the aid library

Routine sterile glove and instrument change at the time of abdominal wound closure to prevent surgical site infection (ChEETAh): a pragmatic, cluster-randomised trial in seven low-income and middle-in

NIHR Global Reserach Health Unit on Global Surgery (2022) CC

The Lancet Vol.400 (2022) p.17-67-1776. Published:October 31, 2022DOI:https://doi.org/10.1016/S0140-6736(22)01884-0. Surgical site infection (SSI) is the most common complication of surgery around the world: ChEETAh trial finds routinely changing gloves and instruments for wound closure could preve... more

Download (410)

View PDF (344)

Decontamination and reprocessing of medical devices for health care facilities: aide-memoire

World Health Organization WHO (2022) CC

Decontamination of medical devices plays an important role in the prevention of health care-associated infections. It includes cleaning, disinfection and/or sterilization. The processes involved in decontamination are complex, require specific infrastructure and equipment, and involve several sequen... more

External Link

WASH and Health working together: a ‘how-to’ guide for neglected tropical disease programmes
recommended

World Health Organization WHO (2023) C_WHO

2nd edition. This toolkit provides step-by-step guidance to NTD programme managers and partners on how to engage and work collaboratively with the WASH community to improve delivery of water, sanitation and hygiene services to underserved population affected by many neglected tropical diseases. The ... more

Download (174)

View PDF (192)

Colaboración entre el sector de WASH y el sector de la salud: Guía práctica para los programas de lucha contra las enfermedades tropicales desatendidas. Segunda edición corregida
recommended

Organización Mundial de la Salud OPS (2023) C_WHO

La atención concedida a la equidad en la Agenda 2030 para el Desarrollo Sostenible obliga a encontrar nuevas formas de ampliar progresivamente los servicios a las poblaciones que no los reciben. Las alianzas satisfactorias entre el sector encargado del suministro de agua, el saneamiento y la higien... more

Download (285)

View PDF (244)

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

World Health Organization WHO (2023) CC

Ebola disease and Marburg disease outbreaks continue to occur in Africa, with increased frequency. In addition to resulting in high mortality and morbidity, the outbreaks generate fear and mistrust about the response activities within the communities affected. Infection prevention and control (IP... more

Community Engagement During Public Health Emergencies Like COVID-19: An Action Framework and Toolkit

Bangladesh Red Crescent Society; BRAC; Government of Bangladesh; UN Children's Fund UNICEF; UN Women; World Health Organization WHO (2023) CC

This handbook offers a simple framework of action for actors in local government, and in particular, health leaders such as Civil Surgeons (CSs) and Upazila Health and Family Planning Officers (UHFPQOs), to take ownership and leadership to combat COVID-19 at each district and upazila respectively, w... more

Infection Prevention and Control Standard Operating Procedures For Cholera Treatment Centres and Units in Malawi (April 2023)

Africa Centres for Disease Control and Prevention Africa CDC; African Union; Government of Malawi; Médecins Sans Frontières; UN Children's Fund UNICEF; World Health Organization WHO (2023) CC

Infection prevention and control (IPC) in a CTC/ CTU IPC are all practical measures taken in the healthcare facility to prevent harm caused by infections to patients, health workers and communities. The main goal of IPC in the cholera response is to • To reduce transmission of health care-as... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Democratic Republic of Timor-Leste Ministry of Health - Comprehensive TB Guidelines for National Tuberculosis Program, V Edition

Government of Timor-Leste; World Health Organization (2023) CC

The Democratic Republic of Timor-Leste has the highest TB incidence rate in the South East Asian Region - 498 per 100,000, which is the seventh highest in the world. In Timor-Leste TB is the eighth most common cause of death. The salient observations are as follows: In 2018, 487 (12.5%) of the... more

Download (174)

View PDF (228)

Lao People’s Democratic Republic-WHO Country Cooperation Strategy 2024–2028

World Health Organization WHO (2023) C_WHO

This country cooperation strategy (CCS) outlines how the World Health Organization (WHO) will work with the Lao People’s Democratic Republic over the next five years (2024–2028), supporting the implementation of the five-year health sector development plans and the Health Sector Reform Strategy ...2021–2030 to attain the Sustainable Development Goals (SDGs) by 2030. The Lao People’s Democratic Republic experienced substantial economic growth in the 30 years prior to the coronavirus disease (COVID-19) pandemic, contributing to reduced poverty and significant progress toward the SDGs. However, the COVID-19 pandemic brought this development to a halt. It was anticipated that the COVID-19 recovery and the tremendous population growth in recent years would provide opportunities for a shift toward more sustainable and inclusive development in the years ahead. In 2023, however, the contrary was the case. Rural residents, including many ethnic minorities, continued to face marginalization because of limited access to education, health care and economic opportunities. Despite the challenges of COVID-19 and other disease outbreaks, the country has made significant improvements in health. Nonetheless, progress has been uneven and not everyone has benefited from these achievements. In the mountainous region, many people lack access to quality health care because of the unequal distribution of well-trained health-care workers. Preventable deaths due to poor-quality health care for children and newborns, infants and mothers remain a concern, as do communicable diseases such as sexually transmitted infections and tuberculosis. The increasing burden of noncommunicable diseases and the health impact of worsening climate change further heighten the need for strengthened and resilient health systems, which are at risk due to an underfunded health sector and weak economy. This CCS aims to address remaining and future challenges as well as health needs while creating an impact that is sustainable. It identifies three strategic priorities and nine deliverables (Table 1) to support the attainment of the national vision of Health for all by all, as articulated in the 9th Health Sector Development Plan 2021–2025. It contributes to the country’s goals to achieve universal health coverage, graduate from least developed country status by 2026 and attain SDGs by 2030. more

Preparedness and Resilience for Emerging Threats Module 1: Planning for respiratory pathogen pandemics

World Health Organization WHO (2024) C_WHO

Through technical consultations with countries and partners, WHO has led the development of Preparedness and Resilience for Emerging Threats Module 1: Planning for respiratory pathogen pandemics. Version 1.0. The Module, currently available as an advanced draft, builds on previous pandemic lessons a... more

Strategic Framework for Enhancing Prevention and Control of mpox, 2024-2027

World Health Organization WHO (2024) C_WHO

Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from ani... more

Download (970)

View PDF (2579)

Control of Communicable Diseases And Prevention of Epidemics

World Health Organization (2002)

Download (1085)

View PDF (1541)

Malaria Vector Control Commodities Landscape

UNITAID Secretariat, World Health Organization World Health Organization (WHO) (2014) C_WHO

2nd edition

Download (994)

View PDF (1180)

A framework for malaria elimination

World Health Organization WHO (2017) C_WHO

External Link

Major Infectious Diseases. Disease Control Priorities, Third Edition : Volume 6

Holmes, King K.; Bertozzi, Stefano; Bloom, Barry R.; Jha, Prabhat World Bank (2017) CC

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective pack... more

Download (658)

View PDF (1287)

Guidelines for malaria vector control
recommended

World Health Organization WHO (2019) C_WHO

these guidelines are updated on 16 February 2021 Please check the new guideline here https://medbox.org/document/who-guidelines-for-malaria#GO

Download (314)

View PDF (512)

Global report on insecticide resistance in malaria vectors: 2010–2016

World Health Organization WHO (2018) C_WHO

As of October 2017, the global database comprised almost 30 000 records, including results from bioassays to measure phenotypic resistance, and biochemical and molecular tests for resistance mechanisms. The current report presents an overview of data on malaria vector resistance for 2010 to 2016. It... more

Safe Management of Wastes from Health-Care Activities, 2nd. ed.
recommended

World Health Organization WHO (2014) C_WHO

Download (1695)

View PDF (4672)

Management of Solid Health-Care Waste at Primary Health-Care Centres

Richard Carr, Yves Chartier, Windy Gancayco Prohom et al. WHO (2005) CC

WASH and Health working together: a ‘how-to’ guide for neglected tropical disease programmes recommended

Colaboración entre el sector de WASH y el sector de la salud: Guía práctica para los programas de lucha contra las enfermedades tropicales desatendidas. Segunda edición corregida recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023 recommended

Guidelines for malaria vector control recommended

Safe Management of Wastes from Health-Care Activities, 2nd. ed. recommended

WASH and Health working together: a ‘how-to’ guide for neglected tropical disease programmes
recommended

Colaboración entre el sector de WASH y el sector de la salud: Guía práctica para los programas de lucha contra las enfermedades tropicales desatendidas. Segunda edición corregida
recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

Guidelines for malaria vector control
recommended

Safe Management of Wastes from Health-Care Activities, 2nd. ed.
recommended